Brought to you by 
Thermo Fisher nets $2.46bn via FOPO; largest for life sciences company
02 Jul 2013
Executive Summary
Thermo Fisher Scientific Inc. netted $2.46bn through the follow-on public offering of 29.6mm common shares (including the overallotment) at $85.50. The proceeds will help fund its proposed $15.2bn acquisition of Life Technologies Corp., which Thermo Fisher announced in April. The transaction is the third-largest medical company FOPO to date behind Mylan (2009) and Roche (2006)--each grossed about $2.9bn--but the biggest for a life sciences/research firm.
Deal Industry
- Laboratory Testing Services
- Research, Analytical Equipment & Supplies
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Thermo Fisher nets $2.46bn via FOPO; largest for life sciences company
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice